Cogent Biosciences, a biotechnology company specializing in precision therapies, has secured a debt financing facility of up to $400 million with SLR Capital Partners to support its growth and the ...

As you can see below, Cogent’s sales grew at an excellent 13% compounded annual growth rate over the last five years. This shows it had high demand, a useful starting point for our analysis.

Moreover, these routes allow Cogent to offer dedicated point-to-point circuits, the most important pillar in providing optical wavelength services. Moreover, by integrating Sprint's assets ...